🎉 M&A multiples are live!
Check it out!

PYC Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for PYC Therapeutics and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

PYC Therapeutics Overview

About PYC Therapeutics

PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.


Founded

2001

HQ

Australia
Employees

5

Website

pyctx.com

Financials

LTM Revenue $14.5M

LTM EBITDA -$41.4M

EV

$357M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

PYC Therapeutics Financials

As of September 2025, PYC Therapeutics reported last 12-month revenue of $14.5M and EBITDA of -$41.4M.

In the same period, PYC Therapeutics achieved -$36.5M in LTM net income.

See PYC Therapeutics valuation multiples based on analyst estimates

PYC Therapeutics P&L

In the most recent fiscal year, PYC Therapeutics reported EBITDA of -$32.8M.

PYC Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See PYC Therapeutics valuation multiples based on analyst estimates
LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $14.5M XXX n/a XXX XXX XXX
Gross Profit n/a XXX n/a XXX XXX XXX
Gross Margin n/a XXX n/a XXX XXX XXX
EBITDA -$41.4M XXX -$32.8M XXX XXX XXX
EBITDA Margin -285% XXX n/a XXX XXX XXX
EBIT -$40.0M XXX -$49.4M XXX XXX XXX
EBIT Margin -275% XXX n/a XXX XXX XXX
Net Profit -$36.5M XXX -$32.8M XXX XXX XXX
Net Margin -251% XXX n/a XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

PYC Therapeutics Stock Performance

PYC Therapeutics has current market cap of AUD 700M (or $456M), and EV of AUD 548M (or $357M).

Market Cap Evolution

PYC Therapeutics Stock Data

As of October 17, 2025, PYC Therapeutics's stock price is AUD 1 (or $1).

See PYC Therapeutics trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$357M $456M XXX XXX XXX XXX $-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

PYC Therapeutics Valuation Multiples

PYC Therapeutics's trades at n/a EV/Revenue multiple, and -12.5x EV/EBITDA.

See valuation multiples for PYC Therapeutics and 15K+ public comps

PYC Therapeutics Financial Valuation Multiples

As of October 17, 2025, PYC Therapeutics has market cap of $456M and EV of $357M.

Equity research analysts estimate PYC Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

PYC Therapeutics has a P/E ratio of -12.5x.

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $456M XXX $456M XXX XXX XXX
EV (current) $357M XXX $357M XXX XXX XXX
EV/Revenue 24.5x XXX n/a XXX XXX XXX
EV/EBITDA -8.6x XXX -12.5x XXX XXX XXX
EV/EBIT -8.9x XXX -8.0x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E -12.5x XXX -15.9x XXX XXX XXX
EV/FCF -9.8x XXX -12.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PYC Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

PYC Therapeutics Margins & Growth Rates

PYC Therapeutics's last 12 month revenue growth is -18%

PYC Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $9.9M for the same period.

PYC Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PYC Therapeutics's rule of X is -330% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for PYC Therapeutics and other 15K+ public comps

PYC Therapeutics Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth -18% XXX n/a XXX XXX XXX
EBITDA Margin -285% XXX n/a XXX XXX XXX
EBITDA Growth 34% XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX -330% XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX $9.9M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

PYC Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

PYC Therapeutics M&A and Investment Activity

PYC Therapeutics acquired  XXX companies to date.

Last acquisition by PYC Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . PYC Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by PYC Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About PYC Therapeutics

When was PYC Therapeutics founded? PYC Therapeutics was founded in 2001.
Where is PYC Therapeutics headquartered? PYC Therapeutics is headquartered in Australia.
How many employees does PYC Therapeutics have? As of today, PYC Therapeutics has 5 employees.
Is PYC Therapeutics publicy listed? Yes, PYC Therapeutics is a public company listed on ASX.
What is the stock symbol of PYC Therapeutics? PYC Therapeutics trades under PYC ticker.
When did PYC Therapeutics go public? PYC Therapeutics went public in 2005.
Who are competitors of PYC Therapeutics? Similar companies to PYC Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of PYC Therapeutics? PYC Therapeutics's current market cap is $456M
What is the current revenue of PYC Therapeutics? PYC Therapeutics's last 12 months revenue is $14.5M.
What is the current revenue growth of PYC Therapeutics? PYC Therapeutics revenue growth (NTM/LTM) is -18%.
What is the current EV/Revenue multiple of PYC Therapeutics? Current revenue multiple of PYC Therapeutics is 24.5x.
Is PYC Therapeutics profitable? Yes, PYC Therapeutics is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of PYC Therapeutics? PYC Therapeutics's last 12 months EBITDA is -$41.4M.
What is PYC Therapeutics's EBITDA margin? PYC Therapeutics's last 12 months EBITDA margin is -285%.
What is the current EV/EBITDA multiple of PYC Therapeutics? Current EBITDA multiple of PYC Therapeutics is -8.6x.
What is the current FCF of PYC Therapeutics? PYC Therapeutics's last 12 months FCF is -$36.4M.
What is PYC Therapeutics's FCF margin? PYC Therapeutics's last 12 months FCF margin is -250%.
What is the current EV/FCF multiple of PYC Therapeutics? Current FCF multiple of PYC Therapeutics is -9.8x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.